Skip to content

Etanercept

Tumor Necrosis Factor Blocker — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Also known as: enbrel, erelzi, etanercept (genetical recombination), etanercept-szzs, TNR 001, TNR-001

EMA approvedFDA approvedPMDA approvedATC L04AB01

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Etanercept is a drug in the Tumor Necrosis Factor Blocker class catalogued in DrugCentral. It was first approved by the FDA in 1998. Its mechanism of action is classified as Tumor Necrosis Factor Receptor Blocking Activity. DrugCentral lists 1 molecular target, including TNF. Recorded indications include Ankylosing spondylitis, Juvenile idiopathic arthritis, Nonradiographic axial spondyloarthritis and Plaque psoriasis.

  • Drug class: Tumor Necrosis Factor Blocker.
  • Mechanism of action: Tumor Necrosis Factor Receptor Blocking Activity.
  • Molecular targets: TNF (1 listed in DrugCentral).
  • Indications: Ankylosing spondylitis, Juvenile idiopathic arthritis, Nonradiographic axial spondyloarthritis, Plaque psoriasis and Psoriasis with arthropathy and others.
  • ATC code: L04AB01 (Tumor necrosis factor alpha (TNF-alpha) inhibitors).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (6)

  • Ankylosing spondylitis
  • Juvenile idiopathic arthritis
  • Nonradiographic axial spondyloarthritis
  • Plaque psoriasis
  • Psoriasis with arthropathy
  • Rheumatoid arthritis

Contraindications (1)

  • Sepsis

Mechanism & targets

Mechanism of action (MoA)Tumor Necrosis Factor Receptor Blocking Activity
Established pharmacologic classTumor Necrosis Factor Blocker

Molecular targets (1)

TargetGeneActionActivity
Tumor necrosis factorTNFinhibitor—

Regulatory approvals (3)

DateAgencyMarketed asApplicantOrphan
2005-01-19PMDA—WYETH LEDERLE JAPAN, WYETH
2000-02-03EMA——
1998-11-02FDA—IMMUNEX

ATC classification

ATC codeTherapeutic hierarchy
L04AB01ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Tumor necrosis factor alpha (TNF-alpha) inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Injection site erythema52083.3
Injection site pain50456.8
Injection site pruritus28648.1
Injection site swelling27080.1
Injection site reaction19752.6
Injection site bruising15965.1
Injection site warmth15328.8
Drug ineffective12968.4
Arthralgia10255.0
Injection site rash8277.6
Injection site haemorrhage8233.1
Wrong technique in product usage process7400.7

Chemical structure

Molecular formula—
Molecular weight—
CAS number185243-69-0
InChIKey—
PubChem CID—

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Etanercept used for?

DrugCentral lists the following indications for Etanercept: Ankylosing spondylitis, Juvenile idiopathic arthritis, Nonradiographic axial spondyloarthritis, Plaque psoriasis, Psoriasis with arthropathy and Rheumatoid arthritis.

How does Etanercept work?

Etanercept is classified as Tumor Necrosis Factor Receptor Blocking Activity; its molecular targets in DrugCentral include TNF (inhibitor).

When was Etanercept first approved?

Etanercept was first approved by the FDA in 1998.

What drug class does Etanercept belong to?

Etanercept is in the Tumor Necrosis Factor Blocker class.

Browse: all drugs starting with E · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

Status—
First approval1998-11-02
AgencyFDA
Targets1
Indications6
Formula—
DrugCentral ID4978
Interactive profile